Agios Pharmaceuticals reported PYRUKYND® net revenue of $8.6 million in Q2 2024 and announced a $905 million purchase agreement for vorasidenib royalty with Royalty Pharma. The company's cash, cash equivalents and marketable securities totaled $645.3 million as of June 30, 2024. They also reported positive topline data from Phase 3 ENERGIZE-T Study and expect to file sNDA based on ENERGIZE and ENERGIZE-T Studies by the end of 2024.
PYRUKYND® net revenue reached $8.6 million, a 5% sequential increase from Q1 2024.
A total of 201 unique patients have completed prescription enrollment forms for PYRUKYND®, representing a 7% increase over the first quarter of 2024.
Agios announced a $905 million purchase agreement with Royalty Pharma for vorasidenib royalty.
Topline data was reported in the Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency.
Agios expects to execute on key milestones and priorities by the end of 2024.
Analyze how earnings announcements historically affect stock price performance